Literature DB >> 15207713

Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression.

Min Kim1, Magda Sgagias, Xiyun Deng, Yun-Jin Jung, Toshiki Rikiyama, Kwangmoon Lee, Michel Ouellette, Kenneth Cowan.   

Abstract

The INK4A/ARF locus on chromosome 9 is a tumor suppressor gene frequently mutated in human cancers. In order to study the effects of p14ARF expression in tumor cells, we constructed a recombinant adenovirus containing p14ARF cDNA (Adp14ARF). Adp14ARF infection of U2OS osteosarcoma cells which has wild type p53 and mutant p14ARF revealed high levels of p14 (ARF) expression within 24h. In addition, Adp14ARF-mediated expressing of p14 (ARF) was associated with increased levels of p53, p21, and mdm2 protein. Growth inhibition assays following Adp14ARF infection demonstrated that the growth of U2OS cells was inhibited relative to infection with control virus. Furthermore, TUNEL analysis as well as PARP cleavage assays demonstrated that Adp14ARF infection was associated with increased apoptosis in U2OS cell line and that it was associated with Adp14ARF induced overexpression of Fas and Fas-L. Addition of Fas-L neutralizing antibody NOK-1 decreased Adp14-mediated cell death, indicating that p14 (ARF) induction of the Fas pathway is associated with increased apoptosis. The finding that Adp14ARF infection did not induce Fas expression in U2OS/E6 and MCF/E6 cells suggests that wild type p53 expression may be necessary for Adp14ARF-mediated induction of Fas. The observation that overexpression of p53 by Adp53 infection in MCF-7 does not induce increased Fas protein levels nor apoptotic cell death suggests that p53 overexpression is required but not sufficient enough for apoptosis. These studies suggest there are other mechanisms other than induction of p53 in ARF-mediated apoptosis and gene therapy using Adp14ARF may be a promising treatment option for human cancers containing wild type p53 and mutant or deleted p14 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207713     DOI: 10.1016/j.bbrc.2004.05.135

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma.

Authors:  Chunbao Li; Li Chunbao; Qianpeng Cheng; Cheng Qianpeng; Jia Liu; Liu Jia; Bin Wang; Wang Bin; Dongfeng Chen; Chen Dongfeng; Yujie Liu; Liu Yujie
Journal:  Mol Cell Biochem       Date:  2012-02-22       Impact factor: 3.396

2.  Mitochondrial p32 is a critical mediator of ARF-induced apoptosis.

Authors:  Koji Itahana; Yanping Zhang
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

3.  Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner.

Authors:  J J Wamsley; C Gary; A Biktasova; M Hajek; G Bellinger; R Virk; N Issaeva; W G Yarbrough
Journal:  Oncogenesis       Date:  2017-04-10       Impact factor: 7.485

4.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

5.  P53 represses human papillomavirus type 16 DNA replication via the viral E2 protein.

Authors:  Craig Brown; Anna M Kowalczyk; Ewan R Taylor; Iain M Morgan; Kevin Gaston
Journal:  Virol J       Date:  2008-01-11       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.